Abstract:Introduction: Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the production of primary prostanoids by blocking the access of arachidonic acid to the active site of the cyclooxygenases (COXs). Because the prostanoids produced by COX-1 appear to play a physiological role (protection of the gastric mucosa, platelet aggregation, vascular homeostasis, maintenance of renal sodium-water balance) while those produced by COX-2 seem mainly to intervene in the inflammatory response and in certain processes associated with cell proliferation, the hypothesis has been put forward that the NSAIDs that are selective COX-2 inhibitors should theoretically be capable of maintaining NSAID therapeutic properties but also have fewer adverse side effects due to the maintenance of prostaglandin production at normal physiological levels. Current knowledge and key points: The hypothesis of COX isoenzyme selectivity has led to a proposed classification for COX inhibitors: 1) COX-1 selective inhibitors (low-dosage aspirin); 2) COX non-selective inhibitors (the majority of classified NSAIDs, which when administered over the long term, e.g., in cases of rheumatoid arthritis, cause duodenal ulcers in 20% of cases and gastric hemorrhage in 1-4% of cases/year); 3) COX-2 preferential inhibitors (meloxicam and nimesulide, which have fewer gastric side effects than standard NSAIDs, but which are not risk-free at high doses); 4) COX-2 selective inhibitors (celecoxib and rofecoxib). Preliminary clinical studies have shown that COX-2 selective inhibitors are as efficient as standard NSAIDs and have fewer adverse digestive side effects, thereby confirming the interest of this proposed classification. In the UK, the aforementioned studies have led to the commercialization of rofecoxib for the treatment of pain and osteoarthritis, while celecoxib has been introduced in medical practice in the USA and other countries for the treatment of rheumatoid arthritis and osteoarthritis. Future prospects and projects: Various epidemiological and laboratory studies have indicated that NSAIDs may be able to reduce the risk of cancer (colorectal cancer in particular) and Alzheimer's disease due to their inhibitory activity on COXs, especially COX-2. The therapeutic contribution of COX-2 specific inhibitors has to be more fully evaluated, particularly as these agents could delay the healing of duodenal ulcers and interfere with several COX-2-induced physiological functions. It is therefore suggested that until further information becomes available, this new class of NSAIDs should be used with caution in certain patient populations.

Recent Research Advances of Nonsteroidal Anti-Inflammatory Drugs (Nsaids)

Progress in research of COX-2,a target for new NSAIDs development

A Novel Class of Anti-Inflammatory and Analgesic Drugs——no-Donating NSAIDs

Recent Development of Nonsteroidal Antiinflammatory Drugs in the Field of Dual COX/5-LOX Inhibitors

Evolution of Novel Non-Steroidal Anti-Inflammatory Drugs with Reduced Gastrointestinal Adverse Effects

Advances in Selective COX-2 Inhibitors

Recent development on COX-2 inhibitors as promising anti-inflammatory agents: The past 10 years

Advances in Search for Adverse Reactions of Non-steroidal Anti-inflammatory Drugs

Safety and rational choice of non-steroidal anti-inflammatory drugs

Advances in the Research on the Cyclooxygenase-2 and 5-Lipoxygenase Dual Inhibitors

[Non-steroidal anti-inflammatory agents with selective inhibitory activity on cyclooxygenase-2. Interest and future prospects]

Recent advancement in the discovery and development of COX-2 inhibitors: Insight into biological activities and SAR studies (2008-2019)

Research progress of one-steroidal anti-inflammatory drugs in osteoarthritis treatment

Natural COX-2 Inhibitors As Promising Anti-Inflammatory Agents: an Update.

Development of Non-Steroidal Anti-Inflammatory Drugs in the Field of Its Quality

Design, synthesis and structure–activity relationship studies of novel and diverse cyclooxygenase-2 inhibitors as anti-inflammatory drugs

Drug Design, Synthesis and Biological Evaluation of Heterocyclic Molecules as Anti-Inflammatory Agents

Synthesis and Anti-inflammatory Activities of Diaryl-substituted-1,2,4-trizole Derivatives

Discovery of Novel NSAID Hybrids As Cpla2/cox-2 Dual Inhibitors Alleviating Rheumatoid Arthritis Via Inhibiting P38 MAPK Pathway

Non-steroidal anti-inflammatory drugs: recent advances in the use of synthetic COX-2 inhibitors

Variability in the response to non-steroidal anti-inflammatory drugs: mechanisms and perspectives